Novartis has signed a deal to acquire US biopharma Endocyte, securing itself access to novel radiopharmaceutical programmes “with significant sales potential”. More: Novartis buys Endocyte for .1 billion Source: News
read moreA week after Pfizer unveiled a reshuffled executive team that’ll report to incoming CEO Albert Bourla, the company says it’s restructuring to simplify management and boost efficiency. And this latest move means job cuts—some 2% of Pfizer’s global workforce of
read moreAs a shortage of epinephrine pens continues to grip the U.K., authorities have agreed to extend the expiration date on a second injector to help ease the situation. More: U.K. fights EpiPen shortage by extending injector expiry dates Source: fierce
read moreIn a lawsuit this week, Minnesota attorney general Lori Swanson alleged that insulin list prices hikes are “deceptive” and have hurt uninsured and underinsured patients with diabetes. She’s asking for injunctive and monetary relief. More: Minnesota AG targets Sanofi, Eli
read moreRoche’s trio of megablockbuster cancer drugs, Herceptin, Rituxan and Avastin, are expected to face copycats in the U.S. in 2019, but a bullish management team said Wednesday that sales will grow “even in a worst-case scenario,” thanks to new drugs
read moreMerck & Co. is joining Big Pharma’s chief digital officer parade. The pharma giant poached Jim Scholefield from Nike to head up global IT and digital strategy—and judging from a reference in Merck’s announcement, he’ll also tackle cybersecurity, a need
read more© 1994 - 2026 B.M. Pharmaceuticals